UK Firm Develops Inhaler to Facilitate Psychedelic Microdosing
Recently, NewTerritory announced that it had developed a wellness product that could be used to inhale psychedelic substances in microdoses. The design studio, which is based in the United Kingdom, anticipates that the drugs could soon be legalized for use in treating various mental health conditions.
The proposal, which the company named Human Nature, imagines how LSD and psilocybin could be administered in small doses to improve an individual’s well-being. Psilocybin is the active compound found in magic mushrooms that causes hallucinations when consumed in large quantities.
In theory, the drugs will be held in biodegradable capsules to be dispensed through an inhaler. Unlike a standard inhaler, this inhaler is pressurized at a low level, which will enable users to breathe in its content in small doses.
The design firm hopes to call attention to the increasing evidence showing that psychedelics could aid in the treatment of mental health conditions such as depression.
In a recent interview, James Ravenhall, the studio’s creative director, stated that researchers starting clinical trials on these substances were finding it hard to advance them because psychedelics are still regulated heavily, which was why the company decided to bring attention to how the drugs could become a part of an individual’s everyday life.
The design company based its product concept on the way CBD extracted from the marijuana plant is now being marketed and sold as a wellness product. Its inhaler, which has been dubbed the spacer, uses breath work. This is a popular wellness practice that helps calm an individual’s mind.
The UK-based company also imagined four capsule types in its concept. These include Relax, which would contain CBD to limit stress hormone production and ease tension; Dream, which would contain melatonin; Create, which would contain psilocybin to aid in creative expression and thinking; and Focus, which would contain LSD to help increase concentration and improve short-term memory.
The company revealed that the capsules would be paired with companion products, which included wearables such as patches, contact lenses or an application with guided meditation, to help track individual physiological changes.
The field also holds commercial potential, with some estimates forecasting that by 2027 the market for psychedelic drugs will have reached a value of $10.7 billion.
The inhaler is made of sustainable materials while its packaging was designed with reference to domestic objects and homeware. NewTerritory has also created a range of products for cannabis consumption, including bongs.
The psychedelics space is quickly becoming populated by different companies with differing areas of focus, such as the way NewTerritory is looking at commercializing an inhaler while Silo Pharma Inc. (OTCQB: SILO) specializes in merging traditional medicine with psychedelics in order to bring new treatments to the market. As these efforts converge, the industry will grow at a rapid pace.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Recently, NewTerritory announced that it had developed a wellness product that could be used to inhale psychedelic substances in microdoses. The design studio, which is based in the United Kingdom, anticipates that the drugs could soon be legalized for use in treating various mental health conditions.
The proposal, which the company named Human Nature, imagines how LSD and psilocybin could be administered in small doses to improve an individual’s well-being. Psilocybin is the active compound found in magic mushrooms that causes hallucinations when consumed in large quantities.
In theory, the drugs will be held in biodegradable capsules to be dispensed through an inhaler. Unlike a standard inhaler, this inhaler is pressurized at a low level, which will enable users to breathe in its content in small doses.
The design firm hopes to call attention to the increasing evidence showing that psychedelics could aid in the treatment of mental health conditions such as depression.
In a recent interview, James Ravenhall, the studio’s creative director, stated that researchers starting clinical trials on these substances were finding it hard to advance them because psychedelics are still regulated heavily, which was why the company decided to bring attention to how the drugs could become a part of an individual’s everyday life.
The design company based its product concept on the way CBD extracted from the marijuana plant is now being marketed and sold as a wellness product. Its inhaler, which has been dubbed the spacer, uses breath work. This is a popular wellness practice that helps calm an individual’s mind.
The UK-based company also imagined four capsule types in its concept. These include Relax, which would contain CBD to limit stress hormone production and ease tension; Dream, which would contain melatonin; Create, which would contain psilocybin to aid in creative expression and thinking; and Focus, which would contain LSD to help increase concentration and improve short-term memory.
The company revealed that the capsules would be paired with companion products, which included wearables such as patches, contact lenses or an application with guided meditation, to help track individual physiological changes.
The field also holds commercial potential, with some estimates forecasting that by 2027 the market for psychedelic drugs will have reached a value of $10.7 billion.
The inhaler is made of sustainable materials while its packaging was designed with reference to domestic objects and homeware. NewTerritory has also created a range of products for cannabis consumption, including bongs.
The psychedelics space is quickly becoming populated by different companies with differing areas of focus, such as the way NewTerritory is looking at commercializing an inhaler while Silo Pharma Inc. (OTCQB: SILO) specializes in merging traditional medicine with psychedelics in order to bring new treatments to the market. As these efforts converge, the industry will grow at a rapid pace.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
